Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

被引：81

作者：

Adams, Sylvia

Schmid, Peter

Rugo, Hope S.

Winer, Eric P.

Loirat, Delphine

Awada, Ahmad

Cescon, David W.

Iwata, Hiroji

Campone, Mario

Nanda, Rita

Hui, Rina

Curigliano, Giuseppe

Toppmeyer, Deborah

O'Shaughnessy, Joyce

Loi, Sherene

Paluch-Shimon, Shani

Card, Deborah

Zhao, Jing

Karantza, Vassiliki

Cortes, Javier

机构：

[1] New York Univ, Perlmutter Canc Ctr, Sch Med, New York, NY USA

[2] Barts Hlth NHS Trust, London, England

[3] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Inst Curie, Paris, France

[6] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[9] Inst Cancerol Ouest Rene Gauducheau, Saint Herblain, France

[10] Univ Chicago, Chicago, IL USA

[11] Westmead Hosp, Westmead, NSW, Australia

[12] Inst Europeo Oncol, Milan, Italy

[13] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[14] Baylor Univ, Med Ctr, Dallas, TX USA

[15] Peter MacCallum Canc Ctr, Melbourne, Australia

[16] Sheba Med Ctr, Tel Hashomer, Israel

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Vall Hebron Univ Hosp, Inst Oncol VHIO, Madrid, Spain

[19] Ramon & Cajal Univ Hosp, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.1008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

1008

引用

页数：5